Over the last 12 years, Emerald BioStructures has developed a highly automated gene-to-structure pipeline. By industrializing the entire process, Emerald is the only CRO capable of processing multiple protein targets, or many variants of the same protein target in parallel. This pipeline allows us the unique ability to crystallize traditionally difficult targets, including membrane proteins, protein-protein complexes, and protein-nucleic acid complexes.